Brief: Valbiotis Announces Last Visit Of Last Patient In Phase II/III Reverse-It Study

Valbiotis SA

13/03/2023 16:41

March 13 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE LAST VISIT OF THE LAST PATIENT IN
THE
PHASE II/III REVERSE-IT STUDY ON TOTUM•63, IN PARTNERSHIP WITH
NESTLÉ HEALTH SCIENCE
    * VALBIOTIS SA - FIRST RESULTS OF STUDY WILL BE RELEASED
BEFORE
END OF FIRST HALF OF 2023, AFTER DATABASE IS FROZEN AND
STATISTICAL ANALYSIS WORK IS COMPLETED
    * VALBIOTIS SA - PRIMARY OBJECTIVE IS TO REDUCE FASTING
BLOOD
GLUCOSE LEVELS AFTER 24 WEEKS OF SUPPLEMENTATION WITH A DAILY
DOSE OF 5 G OF TOTUM 63, IN 3 INTAKES, COMPARED WITH PLACEBO

Source text for Eikon:  ID:nBw2VyPmJa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))